Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy. We show 58 historical shares outstanding datapoints in our BMY shares outstanding history coverage, used to compute BMY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BMY market cap history over the course of time is important for investors
interested in comparing BMY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BMY versus a peer is one thing; comparing
BMY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BMY can fluctuate over the course of history.
With this page we aim to empower investors researching BMY by allowing them to research the BMY market cap history. |
Free BMY Email Alerts:
Video: The Importance of Market Cap
